- Home
- LDWY vs TLPH Comparison
LDWY vs TLPH Comparison
Compare LDWY & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- TLPH
- Stock Information
- Founded
- LDWY 1990
- TLPH 2005
- Country
- LDWY United States
- TLPH United States
- Employees
- LDWY N/A
- TLPH N/A
- Industry
- LDWY Advertising
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- TLPH Health Care
- Exchange
- LDWY Nasdaq
- TLPH Nasdaq
- Market Cap
- LDWY 9.2M
- TLPH 10.6M
- IPO Year
- LDWY 1991
- TLPH 2011
- Fundamental
- Price
- LDWY $5.51
- TLPH $0.54
- Analyst Decision
- LDWY
- TLPH Strong Buy
- Analyst Count
- LDWY 0
- TLPH 1
- Target Price
- LDWY N/A
- TLPH $6.00
- AVG Volume (30 Days)
- LDWY 4.2K
- TLPH 3.4M
- Earning Date
- LDWY 08-28-2025
- TLPH 08-14-2025
- Dividend Yield
- LDWY N/A
- TLPH N/A
- EPS Growth
- LDWY N/A
- TLPH N/A
- EPS
- LDWY N/A
- TLPH N/A
- Revenue
- LDWY $42,183,000.00
- TLPH $27,000.00
- Revenue This Year
- LDWY N/A
- TLPH N/A
- Revenue Next Year
- LDWY N/A
- TLPH $14,533.26
- P/E Ratio
- LDWY N/A
- TLPH N/A
- Revenue Growth
- LDWY 425.12
- TLPH N/A
- 52 Week Low
- LDWY $3.02
- TLPH $0.38
- 52 Week High
- LDWY $6.19
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- LDWY 60.48
- TLPH 65.80
- Support Level
- LDWY $5.39
- TLPH $0.40
- Resistance Level
- LDWY $5.20
- TLPH $0.62
- Average True Range (ATR)
- LDWY 0.22
- TLPH 0.06
- MACD
- LDWY 0.04
- TLPH 0.01
- Stochastic Oscillator
- LDWY 52.45
- TLPH 52.81
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.